STOCK TITAN

Charles River Laboratories (CRL) EVP LaPlume reports bona fide gift of 257 shares

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Charles River Laboratories International, Inc. executive Joseph W. LaPlume, EVP, Corp Strategy & Develop, reported a bona fide gift of 257 shares of common stock on 2026-08-10. The transaction was a disposition made at a reported per-share price of $0.00, leaving him with 31,041 shares of direct ownership afterward.

Positive

  • None.

Negative

  • None.
Insider LaPlume Joseph W
Role EVP, Corp Strategy & Develop
Type Security Shares Price Value
Gift Common Stock 257 $0.00 $0.00
Holdings After Transaction: Common Stock — 31,041 shares (Direct)
Shares gifted 257 shares Bona fide gift of common stock on 2026-08-10
Per-share price reported $0.00 per share Reported transaction price for the gifted shares
Shares owned after transaction 31,041 shares Direct common stock holdings following the gift
Gift transactions count 1 transaction Single bona fide gift reported in this Form 4
Gifted share total 257 shares Total shares involved in gift transactions in this filing
bona fide gift financial
"The transaction code G is described as a bona fide gift."
A bona fide gift is a genuine, voluntary transfer of money, property, or benefits from one party to another made without expectation of repayment, services, or hidden conditions. Investors care because such gifts can affect company disclosures, related‑party transaction rules, tax treatment, and perceived conflicts of interest; think of it like someone giving you a present with no strings attached — but on a corporate scale, auditors and regulators need to verify it really is unconditional.
Form 4 regulatory
"Insider transaction by an officer is reported on Form 4."
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
direct ownership financial
"Ownership type for the reported common stock is direct ownership."

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider transaction did CRL executive Joseph W. LaPlume report?

Joseph W. LaPlume reported a bona fide gift of 257 shares of Charles River Laboratories common stock on 2026-08-10, classified as a disposition with a reported price of $0.00 per share.

How many CRL shares did Joseph W. LaPlume gift in this Form 4 filing?

He gifted 257 shares of Charles River Laboratories common stock. After this bona fide gift transaction, his reported direct holdings totaled 31,041 shares of the company’s common stock.

What are Joseph W. LaPlume’s CRL holdings after the reported gift?

Following the reported bona fide gift of 257 shares, Joseph W. LaPlume’s direct ownership position in Charles River Laboratories common stock is listed as 31,041 shares in the Form 4 data.

Was the CRL insider transaction a sale or a gift of shares?

The transaction is categorized as a bona fide gift (transaction code G), meaning 257 shares were disposed of as a gift rather than sold, with a reported per-share price of $0.00.

Did Joseph W. LaPlume use a Rule 10b5-1 trading plan for this CRL transaction?

The Form 4 data indicates the Rule 10b5-1 checkbox is not affirmed (aff_10b5_one is false), so this reported bona fide gift of 257 shares was not disclosed as made under a Rule 10b5-1 plan.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
LaPlume Joseph W

(Last)(First)(Middle)
C/O CHARLES RIVER LABORATORIES
251 BALLARDVALE STREET

(Street)
WILMINGTON MASSACHUSETTS 01887

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. [ CRL ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
EVP, Corp Strategy & Develop
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/10/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/10/2026G257D$031,041D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
/s/ Joseph W. LaPlume08/11/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)